Cancer MDx Firm Cernostics Seeks to Raise $500K | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer molecular diagnostics firm Cernostics has filed a document with the US Securities and Exchange Commission saying it plans to raise $500,000.

The Pittsburgh-based company, which also has offices in Danville, Penn., did not respond to a request for comment, but in its Form D, it said that it raised $125,000 toward its targeted amount. Securities offered as part of the raise include debt, options, warrants to acquire other securities, and securities to be acquired upon exercise of option, warrants, or other rights to acquire securities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.